Bacteriophage therapy uses viruses that infect bacteria as the therapeutic agent. It is real, it is narrow, and it is worth understanding precisely, including what it does not replace.
How a phage kills
A lytic bacteriophage attaches to a receptor on the bacterial surface, injects its genome, hijacks the host machinery to make more phage, and lyses the cell. Two properties follow directly from that mechanism and they dominate everything else about phage as a therapy:
- It replicates at the site of infection. Dose behaves differently from a small molecule, because the agent amplifies where there is a host to infect and stops when there is not.
- It is extremely specific. Attachment depends on a surface receptor, so host range is often strain level rather than species level. That specificity is the main advantage and the main logistical problem.
Temperate phages, which can integrate into the host genome rather than lysing it, are generally avoided therapeutically because integration can carry genes between bacteria.
Cocktails, host range and matching
Because a single phage may only cover a fraction of clinical isolates of one species, therapy usually means a cocktail of several phages, or a phage selected against the patient's own isolate. Both approaches work and both have consequences: a fixed cocktail can be manufactured and characterised but may miss the isolate; a matched phage fits the isolate but needs a bank, a susceptibility assay and time.
Resistance to phage
Bacteria are not passive. They lose or modify the surface receptor, produce extracellular polysaccharide, run restriction modification systems, and use CRISPR-Cas to cut incoming phage genomes. Resistance appears quickly in vitro.
There is an interesting twist here that matters for discovery: losing the receptor sometimes costs the bacterium something else, such as an efflux pump component or a virulence factor. That trade off is the basis of work on phage and antibiotic combinations, where phage pressure pushes the population toward a phenotype that a small molecule can then kill.
The regulatory and manufacturing picture
Phage does not fit the conventional single molecule framework comfortably. Most human use today is compassionate or within clinical trials, and the questions regulators ask are practical: how is a biological product with a variable composition characterised, how is potency defined, and how is a cocktail revised when resistance appears without starting the process again. These are solvable problems and they are the reason adoption is slower than the scientific interest suggests.
Where small molecules still do the heavy lifting
| Property | Phage | Small molecule antibacterial |
|---|---|---|
| Spectrum | Strain level, needs matching | Species or class level, empirical use possible |
| Dosing | Self amplifying, harder to predict | Conventional pharmacokinetics |
| Manufacturing | Biological, batch variable | Chemical synthesis, well characterised |
| Resistance | Fast in vitro, sometimes with a fitness cost | Varies by mechanism, often spreads on plasmids |
| Regulatory route | Still being defined | Established |
None of this makes phage a curiosity. It makes it a targeted option for specific, often desperate cases, and a genuinely promising partner for small molecules rather than a replacement. Empirical therapy, oral dosing and predictable exposure still belong to chemistry.
If your work is on the small molecule side
The organisms driving interest in phage are the same ones described under carbapenem resistance and superbugs. If you are building a compound series against them, the screen below gives a per strain read with the resistance mechanism named. Membrane active alternatives are covered under antimicrobial peptides.